Rising Disease Burden Is A Catalyst For Growth In RNA-Targeted Small-Molecule Drug Discovery Market: Strengthening the Growth Trajectory of the RNA Targeting Small Molecule Drug Discovery Market

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the RNA Targeting Small Molecule Drug Discovery Market Through 2025?
The market for small molecule drugs targeting RNA has seen a rapid expansion in the past few years. It is projected to escalate from a valuation of $1.76 billion in 2024 to $2.13 billion in 2025, signifying a compound annual growth rate (CAGR) of 20.8%. The past growth trends are credited to a better comprehension of disease genetics, developments in genomics and proteomics, issues of drug resistance, investments funneled into biotechnological and pharmaceutical studies, and the emergence of RNA therapeutics.

What's the Projected Size of the Global RNA Targeting Small Molecule Drug Discovery Market by 2029?
The market for RNA targeting small molecule drug discovery is predicted to accelerate remarkably over the coming years, reaching a market size of "$4.85 billion by 2029 with a steady compound annual growth rate (CAGR) of 22.9%. Factors contributing to this escalation in the forecast period include expanding research on RNA epigenetics, RNA-seq and functional genomics, the incorporation of artificial intelligence (AI), patient-focused strategies, and the use of exosomes in drug delivery. The period is also expected to witness significant developments such as the rise of RNA editing technologies, breakthroughs in CRISPR technology, technological evolution, advancements in the field of RNA biology, and the application of RNA targeting in the treatment of neurodegenerative diseases.

View the full report here:
https://www.thebusinessresearchcompany.com/report/rna-targeting-small-molecule-drug-discovery-global-market-report

Top Growth Drivers in the RNA Targeting Small Molecule Drug Discovery Industry: What's Accelerating the Market?
The growth of the RNA-targeted small molecule drug discovery market is being driven by the rising incidence of cancer, genetic disorders, and viral infections. Cancer comprises a variety of diseases marked by uncontrolled cell growth in the body. Infections caused by tiny infectious agents capable of reproducing only within living cells are referred to as viral infections. RNA targeting-based drug discovery is employed for the treatment of cancer, genetic disorders, and viral infections, since these illnesses are associated with genes and dysfunctional genetic material that can be addressed with drugs created via RNA targeting-based procedures. For example, the World Health Organization, a Switzerland-based intergovernmental body, reported in February 2024 that there had been approximately 20 million new cancer diagnoses and 9.7 million deaths worldwide in 2022. Lung cancer was the most prevalent, with 2.5 million new cases (12.4%), followed by female breast cancer (2.3 million cases, 11.6%), colorectal cancer (1.9 million cases, 9.6%), prostate cancer (1.5 million cases, 7.3%), and stomach cancer (970,000 cases, 4.9%). The projection is that the annual number of new cancer cases will increase by 77%, exceeding 35 million by 2050. Consequently, the rising incidence of cancer, genetic disorders, and viral infections fuels the expansion of the RNA-targeted small molecule drug discovery market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12480&type=smp

What Long-Term Trends Will Define the Future of the RNA Targeting Small Molecule Drug Discovery Market?
The increasing incorporation of artificial intelligence (AI) into drug discovery is emerging as a significant trend in the small-molecule drug discovery market. Key players in the market are utilizing AI technology to expedite the process of drug discovery, thereby maintaining their status in the market. For instance, in May 2023, Google Cloud, the cloud computing section of Google, a U.S. technology firm, introduced the Target and Lead Identification Suite along with the Multiomics Suite to aid in the process of drug discovery. The Multiomics Suite helps to accelerate the identification and analysis of genetic data, allowing companies to develop precision medicines. The Target and Lead Identification Suite helps researchers develop a deeper understanding of the role of amino acids and predict protein structures.

What Are the Main Segments in the RNA Targeting Small Molecule Drug Discovery Market?
The rna targeting small molecule drug discovery market covered in this report is segmented -

1) By Target RNA Type: Messenger RNA (mRNA), Non-Coding RNA (ncRNA), MicroRNA (miRNA), Long Non-Coding RNA (lncRNA)
2) By Technology: CRISPR-Cas9, RNA Aptamers, Small Interfering RNA (siRNA), Ribozymes, Other Technologies
3) By Therapeutic Area: Oncology, Neurology, Infectious Disease, Metabolic Diseases, Genetic Disorders, Other Therapeutic Areas
4) By Delivery Method: Intravenous (IV), Oral, Topical, Other Methods
5) By Application: Research Use, Therapeutic Use, Diagnostic Use, Other Applications

Subsegments:
1) By Messenger RNA (mRNA): Targeting mRNA For Protein Coding, Modulation Of mRNA Stability, mRNA Translation Inhibition
2) By Non-Coding RNA (ncRNA): Long Non-Coding RNA, Small Nuclear RNA, Small Nucleolar RNA
3) By MicroRNA (miRNA): miRNA Inhibition, miRNA Mimics, Targeting Specific miRNA Pathways
4) By Long Non-Coding RNA (lncRNA): lncRNA Modulators, Targeting Specific lncRNA Functions, Therapeutic Applications Of lncRNA

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12480&type=smp

Which Top Companies are Driving Growth in the RNA Targeting Small Molecule Drug Discovery Market?
Major companies operating in the RNA targeting small molecule drug discovery market include F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Moderna Inc., Astellas Pharma Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Sarepta Therapeutics Inc., Evotec A.G., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., Dicerna Pharmaceuticals Inc., Arrakis Therapeutics, Arbutus Biopharma Corporation, H3 Biomedicine Inc., Anima Biotech Inc., Ribometrix Inc., Quark Pharmaceuticals Inc., Regulus Therapeutics Inc., Skyhawk Therapeutics Inc., Accent Therapeutics Inc., Epics Therapeutics, Expansion Therapeutics

Which Regions Will Dominate the RNA Targeting Small Molecule Drug Discovery Market Through 2029?
North America was the largest region in the RNA-targeting small molecule drug discovery market in 2024. The regions covered in the RNA targeting small molecule drug discovery market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12480

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.